Pelthos Therapeutics Inc. revenue by segment PTHS

Annual Quarterly

Pelthos Therapeutics Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Commercial Operations at $16.2 million, 96% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Net Product at $16.2 million, 96% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
Revenue
—
17
—
—
Operating segments
Commercial Operations
—
16
share 96.5%
—
—
Research And Development Operations
—
1
share 3.5%
—
—
Sales mix
Net Product
—
16
share 96.5%
—
—
License And Collaboration
—
1
share 3.5%
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
PTHS (NYSE)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Durham, NC
SEC filer status
, Emerging growth company
SEC CIK
1919246
Former names
Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.